Rise And Fall: PDUFA Fees Go Up But Some GDUFA Levies Come Down In FY 2015
Executive Summary
NDA/BLAs with clinical data will cost 7.7% more starting Oct. 1, bringing the application fee to $2.34 million.
You may also be interested in...
Sandoz’s Biosimilar Filing Is Culmination Of Paradigm Shift In FDA Drug Review
FDA clinical reviewers moved from traditional “new drug” review mode to determining the evidence needed to demonstrate a follow-on product is highly similar to the reference biologic, Sandoz exec says, describing firm’s interactions with FDA on its filgrastim 351(k) application.
FDA User Fees In FY 2014: Burden Per Application Grows As Submission Projections Fall
Agency announces new prescription drug, generic drug and biosimilar rates – with one fee increasing more than 47%.
CellTrans’ Donislecel: Insulin Independence Data May Offer Path To Market In Type 1 Diabetes
Proportion of subjects with freedom from exogenous insulin ‘might support the efficacy’ of the allogeneic islet cellular therapy, US FDA says after concluding that issues in two studies limit interpretability of primary analyses based on severe hypoglycemic events and HbA1c levels. An advisory committee will weigh clinical efficacy, safety and product characterization issues.